Skip to main content

Table 1 Cancer and treatment characteristics of the study population

From: Both comorbidity and worse performance status are associated with poorer overall survival after external beam radiotherapy for prostate cancer

Characteristics
Median age at the time of diagnosis (years; range)70.9 (46.1–89.0)
T stage, n (%)
 T1347 (52.2%)
 T2a-b62 (9.3%)
 T2c92 (13.8%)
 T3147 (22.1%)
 T416 (2.4%)
 unknown1 (0.15%)
N1-disease, n (%)5 (0.75%)
Gleason score, n (%)
 6211 (31.7%)
 7260 (39.1%)
 853 (8.0%)
 9138 (20.8%)
 103 (0.45%)
Percentage of positive biopsy cores, n (%)
 1–10%65 (9.8%)
 11–20%95 (14.3%)
 21–30%82 (12.3%)
 31–40%63 (9.5%)
 41–50%108 (16.2%)
 51–60%45 (6.8%)
 61–70%32 (4.8%)
 71–80%20 (3.0%)
 81–90%30 (4.5%)
 91–100%67 (10.1%)
 Diagnostic transurethral resection of the prostate (TURP)9 (1.4%)
 Missing data49 (7.4%)
Median PSA-level at the time of the diagnosis (range)9.0 (0.9–694.0)
Median time from diagnosis to EBRT, months (range)3.80 (0.77–83.6)
Median duration of ADT, months (range)20.0 (1.6–125.7)
Fractionation type, n (%)
 conventional633 (95.2%)
 hypofractionated32 (4.8%)
Average performance status (ECOG score), n (%)
 0348 (52.3%)
 1281 (42.3%)
 233 (5.0%)
 33 (0.45%)
Charlson Comorbidity Index, n (%)
 0298 (44.8%)
 1190 (28.6%)
 298 (14.7%)
 337 (5.6%)
 420 (3.0%)
 513 (2.0%)
 66 (0.90%)
 72 (0.30%)
 81 (0.15%)